Prostate Cancer Breakthroughs Unveiled at ESMO 2024 – DelveInsight’s Expert Coverage

Several companies have showcased the results of their assets at the ESMO 2024 conference held in Barcelona, Spain, from 13-17 September 2024. DelveInsight Business Research LLP 's comprehensive coverage dives deep into these pivotal discoveries, spotlighting novel therapeutic approaches and late-breaking data poised to change the treatment landscape. One such milestone was the presentation of Phase III PEACE-3 data evaluating Pfizer/Astellas’s XTANDI vs XTANDI Plus XOFIGO.

Abstract Number: LBA1

Title: A randomized multicenter open-label Phase III trial comparing XTANDI vs a combination of XOFIGO and XTANDI in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-III

Data from the Phase III PEACE-3 trial, presented at ESMO 2024, demonstrated that adding XOFIGO to XTANDI led to notable improvements in both rPFS and OS in patients with mCRPC and primarily bone metastases, suggesting this combination as a promising new first-line treatment option for mCRPC. The combination of ENZ with six cycles of Ra233 significantly extended rPFS, increasing the median from 16.4 months with ENZ alone to 19.4 months.

Get the complete trial analysis presented at ESMO 2024, offering a clear vision of what’s ahead in the fight against prostate cancer @ ESMO 2024 Conference Coverage

Therapies like PARP inhibitors, immune checkpoint inhibitors, and combination treatments involving new hormonal therapies and targeted agents are advancing quickly. The shifting landscape points to a growing focus on personalized and combination-based strategies in mCRPC, highlighting the need for Radium-223 and enzalutamide to establish their role in particular patient groups.

Although radiopharmaceuticals have been used for decades in the palliative treatment of prostate cancer, there has been renewed interest in them recently. Continued research into various radioisotopes and targets brings new promise for future therapies.

Other companies such as Bristol Myers Squibb, Exelixis/Ipsen, Amgen, Epizyme, and Pfizer/Astellas have also showcased the results of their drug candidates at the ESMO 2024. A quick summary of these abstracts is given below:

Abstract Number: 1597MO

Title: Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

BMS-986365 (CC-94676) is a novel dual androgen receptor (AR) ligand-directed degrader and antagonist being studied in a heavily pretreated patient population. This therapy aims to target the androgen receptor, a key driver of prostate cancer progression. Early clinical data show promising activity in these patients, who had previously undergone extensive treatments, including chemotherapy and AR-targeted therapies. The study highlights the potential for BMS-986365 as a new treatment option in advanced prostate cancer, particularly for those with limited responses to other therapies.

Abstract Number: LBA67

Title: Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study

The study presented at the ESMO Congress 2024 compared the combination of cabozantinib (C) and atezolizumab (A) with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The key findings were:

• The combination of C+A significantly improved PFS compared to NHT, meeting one of the study’s primary endpoints.
• Although the final OS analysis favored C+A, it did not achieve statistical significance.
• Some subgroups, such as those with liver or bone metastasis, showed a survival advantage with C+A.
• The tolerability of C+A was consistent with other approved treatments for advanced cancers, with treatment-related grade 3-4 adverse events occurring in 40% of the C+A group and 8% of the NHT group

Abstract Number: 1598P?

Title: Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

The study focuses on xaluritamig (AMG 509), a bispecific STEAP1 x CD3 XmAb 2+1 immune therapy designed for patients with metastatic castration-resistant prostate cancer (mCRPC). Early results from an ongoing trial show promise, particularly in the tolerability and efficacy of this therapy. The treatment redirects immune cells to target and eliminate STEAP1-expressing tumor cells, showing clinical benefit in patients. However, the trial is still in its initial stages, and further data are required to assess its long-term efficacy and safety.

Abstract Number: 1603P?

Title: Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)

The Phase Ib/II EZH-1101 study is currently evaluating the combination of tazemetostat (TAZ) and enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC). While the TAZ+ENZ combo extended median radiographic progression-free survival (rPFS) by 2.8 months compared to ENZ alone, the improvement was not statistically significant. The overall response rate (ORR) was also similar between the groups. The most common side effects of the combination were fatigue and nausea. The safety profile aligns with prior findings. Further data is needed to confirm efficacy.

Abstract Number: 1601P?

Title: First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-na?ve prostate cancer (mHNPC)

The data of the Phase II ZZFIRST trial, a randomized phase II study evaluating the combination of enzalutamide (EZ) with or without talazoparib (TALA) in patients with metastatic hormone-na?ve prostate cancer (mHNPC) was presented at the ESMO 2024. Key findings include:

• The combination of EZ and TALA achieved a PSA-complete response rate of 73% compared to 64.7% with EZ alone.
• Median rPFS was not reached for the EZ+TALA arm, while it was 31.1 months for the EZ arm.
• Common adverse events in the EZ+TALA arm included fatigue and anemia, with some patients developing acute leukemia after prolonged treatment.

These results suggest that the combination therapy shows promising antitumor activity and manageable toxicity, warranting further investigation

Get an in-depth analysis of all the prostate cancer abstracts presented at the ESMO 2024 @ Prostate Cancer Analysis and Insights?

Prostate cancer stands as one of the most prevalent cancers among men, affecting approximately 1 in 8 men in the United States during their lifetime. DelveInsight’s analysis revealed that in 2023, the US accounted for 1.5 million diagnosed prevalent cases of prostate cancer. These are expected to increase by 2034 owing to increasing aging populations, improved screening methods leading to earlier detection, changes in lifestyle and environmental factors, and advancements in medical technology allowing for better diagnosis and treatment.

Prostate cancer is most frequently diagnosed among men aged 65–74 years. Analysis indicates that age-specific data differs across various geographic regions. In the US, prostate cancer was least prevalent among individuals aged over 84 years, whereas in Japan, the lowest number of cases were observed in the age group of 54 years or younger.

Currently approved drugs for metastatic prostate cancer include Astellas/Pfizer’s XTANDI; Janssen’s ZYTIGA, ERLEADA, and AKEEGA; Bayer’s NUBEQA; AstraZeneca’s LYNPARZA; Pharma& Schweiz’s RUBRACA; Pfizer’s TALZENNA; AstraZeneca/Merck’s LYNPARZA; Myovant Sciences’ ORGOVYX; Sanofi’s JEVTANA; and Novartis' radioligand therapy, PLUVICTO.

Several key companies such as Pfizer, Bayer, Curium, Merck and Orion, Telix Pharmaceuticals, Exelixis, Ipsen, AstraZeneca, AB Science, Fusion Pharma, Lantheus Holdings and Lilly, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Candel Therapeutics, Arvinas, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, Oncternal Therapeutics, Merck, LAVA Therapeutics, Essa Pharma, Clarity Pharmaceuticals, Astellas Pharma, DualityBio, Celgene, Fortis Therapeutics, Inc., ORIC Pharmaceuticals, Ambrx, Inc., Amgen, Crescendo Biologics Ltd., Syncromune, Inc., Full-Life Technologies GmbH, Poseida Therapeutics, Inc., Janssen Research & Development, LLC, MacroGenics, and others are currently working with their novel prostate cancer drug candidates to improve the treatment landscape.

Keen to know more about prostate cancer? Get all the insights at Prostate Cancer Market Report

Stay informed with DelveInsight as we unravel the science driving the future of oncology care!